Development and Pilot Testing of a Cognitive-Behavioral Therapy Digital Service for Body Dysmorphic Disorder.

Autor: Wilhelm S; Massachusetts General Hospital/Harvard Medical School. Electronic address: swilhelm@mgh.harvard.edu., Weingarden H; Massachusetts General Hospital/Harvard Medical School., Greenberg JL; Massachusetts General Hospital/Harvard Medical School., McCoy TH; Massachusetts General Hospital/Harvard Medical School., Ladis I; Massachusetts General Hospital/Harvard Medical School., Summers BJ; Massachusetts General Hospital/Harvard Medical School., Matic A; Telefónica Innovación Alpha, S.L., Harrison O; Telefónica Innovación Alpha, S.L.
Jazyk: angličtina
Zdroj: Behavior therapy [Behav Ther] 2020 Jan; Vol. 51 (1), pp. 15-26. Date of Electronic Publication: 2019 Aug 07.
DOI: 10.1016/j.beth.2019.03.007
Abstrakt: Body dysmorphic disorder (BDD) has a severe presentation and chronic course when untreated. Although effective BDD treatments exist, most individuals do not have access to them. We therefore developed and pilot tested the first smartphone-delivered individual cognitive-behavioral therapy (CBT) treatment for adults with BDD. The digital service was developed via user-centered design, integrating input from engineering, design, and psychology experts, plus BDD patient consultants. We conducted a 12-week open pilot trial (N = 10) to describe preliminary results for feasibility, acceptability, and treatment outcome. Attrition rates (0%) and feedback on usability and satisfaction indicated that smartphone-based CBT for BDD may be feasible, acceptable, and satisfactory. Initial results suggest that smartphone-based CBT for BDD may hold promise for improving BDD symptom severity, BDD-related insight, functional impairment, and quality of life, as scores from baseline to posttreatment improved with large-to-very large effects; depression improved with a medium effect. Ninety percent of participants were responders at posttreatment and 3-month follow-up. Smartphone-based CBT for BDD may have strong potential as a standardized, low cost, and accessible treatment for this debilitating illness. A test of efficacy is merited as a next step, using a well-powered, randomized control trial design.
(Copyright © 2019. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: